Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antisense battles small molecule for slice of rare lipid disorder market.

Literature DB >> 23471047

Antisense battles small molecule for slice of rare lipid disorder market.

Gunjan Sinha.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2013 PMID： 23471047 DOI： 10.1038/nbt0313-179

Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908

× No keyword cloud information.

4 in total

1. Biologics inch toward cholesterol-lowering market.

Authors: Ken Garber
Journal: Nat Biotechnol Date: 2012-04-10 Impact factor: 54.908

2. Safety signal dampens reception for mipomersen antisense.

Authors: Jim Kling
Journal: Nat Biotechnol Date: 2010-04 Impact factor: 54.908

3. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.

Authors: Frederick J Raal; Raul D Santos; Dirk J Blom; A David Marais; Min-Ji Charng; William C Cromwell; Robin H Lachmann; Daniel Gaudet; Ju L Tan; Scott Chasan-Taber; Diane L Tribble; Joann D Flaim; Stanley T Crooke
Journal: Lancet Date: 2010-03-20 Impact factor: 79.321

4. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.

Authors: Marina Cuchel; Emma A Meagher; Hendrik du Toit Theron; Dirk J Blom; A David Marais; Robert A Hegele; Maurizio R Averna; Cesare R Sirtori; Prediman K Shah; Daniel Gaudet; Claudia Stefanutti; Giovanni B Vigna; Anna M E Du Plessis; Kathleen J Propert; William J Sasiela; LeAnne T Bloedon; Daniel J Rader
Journal: Lancet Date: 2012-11-02 Impact factor: 79.321

4 in total

5 in total

Review 1. The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations.

Authors: Anandita Agarwala; Peter Jones; Vijay Nambi
Journal: Curr Atheroscler Rep Date: 2015-01 Impact factor: 5.113

Antisense battles small molecule for slice of rare lipid disorder market.

1. Biologics inch toward cholesterol-lowering market.

2. Safety signal dampens reception for mipomersen antisense.

3. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.

4. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.

Review 1. The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations.

2. Spinal muscular atrophy approval boosts antisense drugs.

Review 3. Induced protein degradation: an emerging drug discovery paradigm.

Review 4. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.

5. Structure and decoy-mediated inhibition of the SOX18/Prox1-DNA interaction.